X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DIVIS LABORATORIES AJANTA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 24.9 30.0 83.1% View Chart
P/BV x 10.3 5.2 197.7% View Chart
Dividend Yield % 0.6 1.0 61.3%  

Financials

 AJANTA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DIVIS LABORATORIES
Mar-17
AJANTA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7201,222 140.8%   
Low Rs1,103784 140.7%   
Sales per share (Unadj.) Rs194.6153.1 127.1%  
Earnings per share (Unadj.) Rs45.239.9 113.2%  
Cash flow per share (Unadj.) Rs50.344.6 112.8%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.0 56.8%  
Book value per share (Unadj.) Rs132.0201.8 65.4%  
Shares outstanding (eoy) m88.77265.47 33.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.36.6 110.7%   
Avg P/E ratio x31.225.1 124.3%  
P/CF ratio (eoy) x28.122.5 124.8%  
Price / Book Value ratio x10.75.0 215.1%  
Dividend payout %17.725.0 70.7%   
Avg Mkt Cap Rs m125,299266,266 47.1%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m2,5704,687 54.8%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m17,27540,643 42.5%  
Other income Rs m166749 22.2%   
Total revenues Rs m17,44241,392 42.1%   
Gross profit Rs m5,80714,460 40.2%  
Depreciation Rs m4511,233 36.5%   
Interest Rs m4923 216.4%   
Profit before tax Rs m5,47413,953 39.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4603,349 43.6%   
Profit after tax Rs m4,01410,604 37.9%  
Gross profit margin %33.635.6 94.5%  
Effective tax rate %26.724.0 111.1%   
Net profit margin %23.226.1 89.1%  
BALANCE SHEET DATA
Current assets Rs m7,63940,105 19.0%   
Current liabilities Rs m2,7156,595 41.2%   
Net working cap to sales %28.582.5 34.6%  
Current ratio x2.86.1 46.3%  
Inventory Days Days43119 36.5%  
Debtors Days Days7981 97.5%  
Net fixed assets Rs m6,91419,995 34.6%   
Share capital Rs m177531 33.3%   
"Free" reserves Rs m11,44253,043 21.6%   
Net worth Rs m11,72153,574 21.9%   
Long term debt Rs m1490-   
Total assets Rs m14,81461,585 24.1%  
Interest coverage x112.9618.4 18.3%   
Debt to equity ratio x00-  
Sales to assets ratio x1.20.7 176.7%   
Return on assets %27.417.3 158.9%  
Return on equity %34.219.8 173.0%  
Return on capital %46.526.1 178.4%  
Exports to sales %55.10-   
Imports to sales %6.025.2 23.8%   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,03810,259 10.1%   
Fx inflow Rs m10,42235,384 29.5%   
Fx outflow Rs m1,67810,399 16.1%   
Net fx Rs m8,74424,985 35.0%   
CASH FLOW
From Operations Rs m3,26411,493 28.4%  
From Investments Rs m-2,093-11,372 18.4%  
From Financial Activity Rs m-1,186-93 1,273.6%  
Net Cashflow Rs m-1528 -52.1%  

Share Holding

Indian Promoters % 73.8 52.0 141.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.8 13.1%  
FIIs % 7.6 19.0 40.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.2 98.8%  
Shareholders   20,968 31,796 65.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  SANOFI INDIA  ALKEM LABORATORIES  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS